180 related articles for article (PubMed ID: 16520105)
1. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Papapoulos SE; Schimmer RC
Ann Rheum Dis; 2007 Jul; 66(7):853-8. PubMed ID: 17277001
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
Cooper A; Drake J; Brankin E;
Int J Clin Pract; 2006 Aug; 60(8):896-905. PubMed ID: 16800837
[TBL] [Abstract][Full Text] [Related]
3. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
Alves C; Mendes D; Penedones A; Oliveira T; Donato A; Batel-Marques F
Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890
[TBL] [Abstract][Full Text] [Related]
5. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
Klaus J; Reinshagen M; Herdt K; Schröter C; Adler G; von Boyen GB; von Tirpitz C
World J Gastroenterol; 2011 Jan; 17(3):334-42. PubMed ID: 21253392
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation.
Kinov P; Boyanov M
Int J Womens Health; 2012; 4():167-74. PubMed ID: 22532780
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.
Dalle Carbonare L; Zanatta M; Gasparetto A; Valenti MT
Drug Healthc Patient Saf; 2010; 2():121-37. PubMed ID: 21701624
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ibandronate: a long term confirmation.
Di Munno O; Delle Sedie A
Clin Cases Miner Bone Metab; 2010 Jan; 7(1):23-6. PubMed ID: 22461287
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites.
Shi S; Duan H; Ou X
Biomed Pharmacother; 2024 Jun; 175():116699. PubMed ID: 38705129
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic and oral contraceptive drug interactions: Is there a need for concern?
Zhanel GG; Siemens S; Slayter K; Mandell L
Can J Infect Dis; 1999 Nov; 10(6):429-33. PubMed ID: 22346401
[TBL] [Abstract][Full Text] [Related]
11. Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule.
Vita R; Benvenga S
Endocr Pract; 2014 Mar; 20(3):e38-41. PubMed ID: 24246350
[TBL] [Abstract][Full Text] [Related]
12. Minocycline-induced renal polyarteritis nodosa.
Tabriziani H; Wilcox CS; Gilbert ON; Lipkowitz MS
BMJ Case Rep; 2012 Aug; 2012():. PubMed ID: 22891025
[TBL] [Abstract][Full Text] [Related]
13. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
14. Do antibiotics decrease effectiveness of oral contraceptives?
Cottet C
Oreg Nurse; 1996 Sep; 61(3):4-5. PubMed ID: 9006212
[TBL] [Abstract][Full Text] [Related]
15. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Chung HY; Koo J; Kwon SK; Kang MI; Moon SH; Park JY; Shin CS; Yoon BK; Yoon HK; Chang JS; Chung YS; Park HM
Clin Interv Aging; 2013; 8():597-603. PubMed ID: 23761968
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.
Fraser LA; Vogt KN; Adachi JD; Thabane L
Ther Clin Risk Manag; 2011; 7():157-66. PubMed ID: 21691586
[TBL] [Abstract][Full Text] [Related]
17. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
19. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
